Cambridge Healthtech Institute’s 20th Annual

Targeting Protein-Protein Interactions

Medicinal Chemistry Progress against Difficult-to-Drug Targets

April 21-22, 2027


CHI’s Targeting Protein-Protein Interactions conference highlights small molecule compounds making therapeutic progress against protein-protein or protein-nucleic acid complexes. Such protein-protein interactions (PPIs) when mutated or improperly regulated, contribute to many conditions in cancer, autoimmunity, and neurodegeneration—and have traditionally been difficult to target with small molecule agents. While the meeting's focus will be on promising small molecules targeting intracellular PPIs, where the cell-permeability "superpower" of small molecules lies, difficult-to-drug membrane protein targets will also be covered. The PPI conference also highlights applications and case studies of biophysical methods, fragment-based drug discovery (FBDD), and other medicinal chemistry tools driving progress against PPIs. The companion Small Molecule Discovery Technologies conference in the first half of Drug Discovery Chemistry covers similar tools but with more focus on the methodological innovations enabling PPI tractability.

Coverage will likely include:

  • Origin stories of small molecules targeting PPI contributors to neurodegeneration, autoimmunity, inflammation, and cancer, that are in or close to clinical development
  • Case studies of promising PPI-targeted small molecule compounds from FBDD campaigns
  • Stabilizers or Glues (non-degrading) of disease-relevant PPIs
  • Targeting transcriptions factors, complexes or protein-DNA interactions with small molecules
  • Structure-based drug design (SBD) and rational drug design case studies for difficult membrane protein targets (GPCRs, Ion Channels)
  • CryoEM applications to complex membrane protein-targeted drug discovery

The deadline for priority consideration is October 5, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners